缺少GSK3β会扩大肥胖的脂肪血管,以缓解代谢障碍
Li Wang1,2,3, Jiajia Li1, Ping Tang1
1Department of Biomedical Sciences, Faculty of Health Sciences (L.W., J.L., P.T., D.Z., L.T., Y.W., L.D.), University of Macau, China.
Circulation research
|December 4, 2024
概括
在脂肪细胞中删除GSK3β可以改善血管化,并减少肥胖的代谢问题. 这项研究突出了GSK3ββ.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 肥胖研究的研究.
- 脂肪组织生物学 脂肪组织生物学
- 血管生物学 血管生物学
背景情况:
- 健康的血管系统对于脂肪组织 (AT) 扩张至关重要,以防止代谢并发症.
- 糖原合成酶激酶-3β (GSK3β) 已知具有细胞作用,但其在AT和体内平衡中的功能尚不清楚.
研究的目的:
- 研究GSK3β在脂肪组织 (AT) 中的作用及其对代谢平衡的影响.
- 为了确定脂肪细胞中的GSK3β是否影响血管化和与肥胖相关的代谢障碍.
主要方法:
- 为GSK3β (GSK3βADKO) 和GSK3α (GSK3αADKO) 生成脂肪细胞特定的淘汰赛小鼠.
- 在肥胖的GSK3βADKO小鼠和培养细胞上进行了全身代谢分析,RNA测序,血管 perfusion 研究和体外测定.
主要成果:
- 脂肪细胞特异性的GSK3β淘汰扩大了AT血管化,并减轻了与肥胖有关的代谢障碍.
- 脂肪细胞中的GSK3β缺乏激活AMPK/HIF-2α/VEGF/VEGFR2轴,促进血管生成和改善AT微环境.
- 这导致肥胖AT患者的形蛋白增加,纤维化减少,反应性氧物种和ER压力.
结论:
- 在脂肪细胞中删除GSK3β通过AMPK/HIF-2α/VEGF/VEGFR2通路促进肥胖AT的血管扩张.
- 这种血管化改善了当地的AT微环境,减少了炎症并改善了与肥胖相关的代谢障碍.
相关概念视频
Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


